Buy Solifenacin

Solifenacin

What is Solifenacin?

Solifenacin is a prescription medication used to treat symptoms of an overactive bladder. It contains Solifenacin Succinate as its active component. The drug is supplied as an oral pill in strengths of 5 mg and 10 mg. In Hong Kong, Solifenacin is regulated by the Medicines and Healthcare Products Regulatory Authority (HKHA) and is classified as a prescription-only medicine (POM). It belongs to the therapeutic class of Urological Health agents, specifically the antimuscarinic (anticholinergic) group that reduces involuntary bladder contractions.

How Solifenacin Works in the Body

Solifenacin is an antimuscarinic agent that selectively blocks the muscarinic M3 receptors in the detrusor muscle of the urinary bladder. By inhibiting these receptors:

• Detrusor muscle activity decreases, reducing involuntary contractions that cause urgency and frequency.
• Bladder capacity increases, allowing more urine to be stored before the urge to void.
• The drug’s effect begins within a few hours after the first dose, with peak plasma concentrations occurring around 3-5 hours, and a half-life of approximately 45-68 hours, supporting once-daily dosing.

Treating Overactive Bladder with Solifenacin

Solifenacin is approved in Hong Kong for the treatment of overactive bladder (OAB) with symptoms of urinary urgency, frequency, and urge urinary incontinence in adults. Clinical studies have demonstrated that daily use improves bladder control and reduces the number of incontinence episodes. The medication is intended for patients who have not achieved adequate symptom control with behavioral therapies alone.

Patient Suitability and Contraindications

Who Should Use Solifenacin?

• Adults experiencing OAB symptoms who require pharmacologic therapy after non-drug measures (bladder training, fluid management) have been tried.
• Patients who can tolerate anticholinergic effects such as dry mouth or constipation.

Absolute Contraindications

• Known hypersensitivity to solifenacin succinate or any excipients.
• Severe urinary retention or significant bladder outflow obstruction.
• Gastric retention or severe gastrointestinal motility disorders.
• Severe hepatic impairment (Child-Pugh class C).

Relative Contraindications

• Moderate hepatic impairment (Child-Pugh class B) - dose may need adjustment.
• Renal impairment - use with caution; no dose change required unless severe.
• Narrow-angle glaucoma - anticholinergic effect may increase intra-ocular pressure.
• Pregnancy and lactation - safety not established; use only if the potential benefit justifies the risk. Solifenacin is generally avoided during pregnancy (category C).

Special Populations

• Elderly patients: Start with the lower 5 mg dose due to increased sensitivity to anticholinergic side effects.
• Patients with cognitive impairment: Monitor closely as anticholinergic burden can affect cognition.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Dry mouth - often the most frequently reported effect.
• Constipation - may be managed with dietary fiber and adequate hydration.
• Blurred vision - generally mild and transient.
• Drowsiness or fatigue - reported in a minority of patients.

Serious Adverse Events

• Urinary retention - may require catheterisation; seek immediate medical attention if unable to void.
• Severe allergic reactions - rash, angioedema, or anaphylaxis.
• Cardiac effects - rare reports of tachycardia; monitor in patients with pre-existing arrhythmias.

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin, ritonavir) can increase solifenacin plasma concentrations → dose reduction may be needed.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy.
• Other anticholinergic agents (e.g., antihistamines, tricyclic antidepressants) can increase anticholinergic burden → monitor for additive dryness, constipation, or confusion.
• P-glycoprotein inhibitors (e.g., quinidine) may modestly raise solifenacin levels.

Food and Lifestyle Interactions

• Solifenacin can be taken with or without food; food does not significantly affect absorption.
• Alcohol does not have a direct interaction but may exacerbate dizziness; moderation is advised.
• Patients should avoid driving or operating heavy machinery if they experience dizziness or blurred vision.

How to Take Solifenacin

• Standard dosing: Start with 5 mg once daily. If symptoms are not adequately controlled after 1-2 weeks, the dose may be increased to 10 mg once daily. Do not exceed 10 mg per day.
• Administration: Swallow the tablet whole with a glass of water. Do not crush or chew.
• Timing: Take the medication at the same time each day to maintain steady blood levels.
• Special populations:
• Elderly: Begin with 5 mg; titrate cautiously.
• Renal or hepatic impairment: Review dose with a healthcare provider; no routine dose reduction for mild-to-moderate impairment, but severe hepatic dysfunction is contraindicated.
• Missed dose: Take the missed dose as soon as remembered unless it is near the time of the next scheduled dose. Do not double the dose.
• Overdose: Symptoms may include severe anticholinergic effects (dry mouth, dilated pupils, tachycardia, urinary retention, confusion). Seek emergency medical attention; supportive care is the mainstay of treatment.
• Discontinuation: No taper is required. If therapy is stopped, symptoms of OAB may return; discuss alternative management with a clinician.

Monitoring and Follow-Up

• Clinical assessment: Evaluate bladder symptom improvement after 2-4 weeks of therapy.
• Renal and hepatic function: Check baseline liver enzymes and renal function; repeat if clinically indicated, especially in patients with existing impairment.
• Urinary retention: Monitor post-void residual volume if patients report difficulty voiding.
• Adverse effects: Counsel patients to report persistent dry mouth, constipation, or any signs of urinary retention promptly.

Storage and Handling

• Store tablets at room temperature (15-30 °C), protected from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiry date printed on the packaging.
• For safe disposal, follow local pharmaceutical waste guidelines or return to a pharmacy.

Medication-Specific Glossary

Anticholinergic

A drug that blocks the action of the neurotransmitter acetylcholine at muscarinic receptors, reducing involuntary muscle contractions such as those in the bladder.

Overactive Bladder (OAB)

A syndrome characterized by urgency, frequency, and urge urinary incontinence without an underlying infection or structural abnormality.

CYP3A4

An enzyme in the liver and intestines that metabolizes many medications; inhibitors or inducers of CYP3A4 can alter solifenacin blood levels.

Medical Disclaimer

This article provides educational information about Solifenacin and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.